6 Results for "

type 2 diabetic nephropathy

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "type 2 diabetic nephropathy" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-N2421
CAS No.: 523-92-2
Synonyms: 5-O-Methyl-myo-inositol
Sequoyitol (5-O-Methyl-myo-inositol) is an orally active hypoglycemic agent and antioxidant. Sequoyitol can be isolated from herbaceous plants. Sequoyitol downregulates the expression of NF-κB and TGF-β1, reduces ROS production and malondialdehyde levels, and enhances total antioxidant capacity. Sequoyitol activates the insulin signaling pathway, including the phosphorylation of IR, IRS1 and Akt. Sequoyitol increases serum insulin levels, inhibits hepatic glucose production, and promotes cellular glucose uptake. Sequoyitol antagonizes TNFα-induced inhibition of the insulin signaling pathway, and decreases blood urea nitrogen and serum creatinine levels. Sequoyitol elicits potential peaks in the chemosensors of adult and larval Atrophaneura alcinous, and acts as an oviposition stimulant for female Atrophaneura alcinous. Sequoyitol can be used in research related to type 2 diabetes, insulin resistance, hyperglycemia, impaired glucose tolerance and diabetic nephropathy .
loading...
    loading...
Cat. No.: HY-14923
CAS No.: 473289-62-2
Synonyms: AVE 7688
Research Areas:  

Metabolic Disease

Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy .
loading...
    loading...
Cat. No.: HY-100819
CAS No.: 1365266-79-0
Target:  

CCR

Research Areas:  

Metabolic Disease

RO5234444 is an orally active CCR2 antagonist, with IC50s of 22nM for human CCR2 and 161 nM for mouse CCR2. RO5234444 alleviates glomerulosclerosis, reduces albuminuria, and significantly improves the glomerular filtration rate (GFR) in the uninephrectomized (1K) type 2 diabetic db/db mouse model. RO5234444 can be used for the study of type 2 diabetic nephropathy .
loading...
    loading...
Cat. No.: HY-P11736
CAS No.: 1489241-80-6
Target:  

NF-κB

Research Areas:  

Metabolic Disease

mcIRBP-9 is an orally active NF-κB inhibitor. mcIRBP-9 reduces the levels of TNF-α, IL-1β and TGF-β1 in renal tissues, and decreases LPS-induced IL-1β production. mcIRBP-9 can be used in research related to diabetic nephropathy and type 2 diabetes mellitus .
loading...
    loading...
Cat. No.: HY-P12142
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease Endocrinology

GLP-1 receptor agonist D13 is a long-acting GLP-1R agonist peptide conjugated with a C20 fatty acid chain. It activates GLP-1R-mediated cAMP signaling in HEK293 cells, with an EC50 of 0.036 nM. GLP-1 receptor agonist D13 can be used in studies related to type 2 diabetes, diabetic nephropathy and obesity .
loading...
    loading...
Cat. No.: HY-124487
CAS No.: 1062624-71-8
GK-136901 is an orally active, dual Nox1/Nox4 NADPH oxidase inhibitor with a Ki of 160 nM for Nox1 and 165 nM for Nox4. GK-136901 potently blocks high glucose-induced intracellular reactive oxygen species production, p38-MAPK phosphorylation, and upregulation of TGF-β1/2 and fibronectin (fibronectin) in renal cells. GK-136901 also inhibits the proliferation of mouse pulmonary vascular cells under hypoxic conditions. GK-136901 is applicable to the research on the pathogenesis of type 2 diabetic nephropathy, high glucose-related renal lesions and pulmonary hypertension .
loading...
    loading...